We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Intarcia Appeals FDA Panel Decision on Diabetes Product Citing “Misleading” Claims
Intarcia Appeals FDA Panel Decision on Diabetes Product Citing “Misleading” Claims
Intarcia Therapeutics has alleged that the FDA presented “false and misleading” claims about its product and has appealed an FDA advisory committee opinion rejecting its new drug application for ITCA 650 (exenatide in DUROS device), a diabetes drug-device combination.